Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Journal of Chengde Medical College》 2018-01
Add to Favorite Get Latest Update


YANG Zeng-xin;ZHENG Ruo-long;Internal Medicine-Cardiovascular Department, Jiangyin People's Hospital;  
Objective: To evaluate the effectiveness and safety of Naoxintong for treating patients with clopidogrel resistance after percutaneous coronary intervention(PCI). Methods: 108 patients with clopidogrel resistance after PCI were randomly divided into clopidogrel group, Naoxintong group and ticagrelor group with 36 patients in each group. After PCI, the patients in clopidogrel group took 150 mg(qd) clopidogrel; the patients in Naoxintong group took 150 mg(qd) clopidogrel and 0.8 mg Naoxintong capsule(tid); the patients in ticagrelor group took 90 mg ticagrelor(bid). The platelet aggregation rate(1 week and 1 month after treatment) and adverse reactions of patients in 3 groups were recorded. Results: The platelet aggregation rate of patients in Naoxintong group and ticagrelor group after treatment were all obviously lower than that before treatment(P0.05); also obviously lower than clopidogrel group after treatment(P0.05). In addition, the platelet aggregation rate of patients in ticagrelor group 1 month after treatment was obviously lower than Naoxintong group(P 0.05). There was no significant difference in incidence rate of bleeding events between the three groups(P 0.05); But the incidence rate of dyspnea of ticagrelor group(11.11%, 4/36) was obviously higher than clopidogrel group and Naoxintong group(P 0.05). Conclusions:Naoxintong can improve the antiplatelet effects of CR patients after PCI and has less side effects,so it is worthy of clinical expansion.
【CateGory Index】: R541.4
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved